Searle To Discuss Adding Celebrex 13-Month Safety Data To Label With FDA

Searle plans to approach FDA with data from a 13-month trial comparing the ulcer incidence for Celebrex to other nonsteroidal anti-inflammatory drugs, seeking a label change for the COX-2 inhibitor.